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 •  A 47-year-old female was admitted for evaluation of 
persistent abdominal cramping and bloating. 
 •  CT Abdomen and Pelvis (Image 1a) showed 3.1 x 2.6 x 2.7 
cm enhancing soft tissue mesenteric mass involving adjacent 
small bowel loops with features of small bowel obstruction. 
 •  Surgical evaluation showed an infiltrative small bowel mass 
in the proximal ileum causing mechanical obstruction with 
proximal bowel dilation and adjacent lymphadenopathy. 
 •  She underwent mesenteric mass, small bowel and lymph 
node resection with histopathology showing a low-grade 
neuroendocrine tumor. 
 •  Further evaluation with 68Ga-DOTATATE PET/CT (Image 2a 
and 2b) was suggestive of extensive hepatic metastases 
(confirmed by biopsy) which were not reported on the CT 
Abdomen (Image 1b). 
 •  She is managed on chemotherapy as an outpatient.
 •  Gastroenteropancreatic (GEP) neuroendocrine 
tumors (NETs) are a group of neoplastic tumors 
arising from the diffuse neuroendocrine system 
of the gastrointestinal tract and pancreas. 
 •  Although considered to be a rare entity, the 
incidence of GEP NETs has increased by 720% 
according to the US Surveillance Epidemiology 
and End Results (SEER) databases owing to 
increased awareness and improved diagnostic 
techniques. 
 •  Assessment of the location of GEP NETs are 
crucial in the management of GEP NETs
 •  Various imaging modalities like Octreoscan®, 
18F FDG PET/CT, CT, MRI and the recently 
approved 68Ga-DOTATATE PET/CT are 
currently used for diagnosis of GEP NETs. 
 •  68Ga-DOTATATE PET/CT provides enhanced diagnostic information 
compared to other approved imaging and it has been proven to 
have significant impact in management of patients with NETs.  
 •  Haug et al showed 68Ga-DOTATATE PET/CT to be more sensitive, 
specific and accurate in cases of GEP NETs. 
 •  Our case series illustrates the importance of further evaluating 
confirmed cases of GEP NETs with 68Ga-DOTATATE PET/CT scan, 
as this may change staging and ultimate treatment decisions.  
 •  It also highlights the importance of keeping GEP NETs on the 
differential in evaluating patients with persistent abdominal pain 
despite extensive workup, as it was the presenting symptom in all 
of our cases.
 Case 01
 •  A 72-year-old female was admitted for five months of 
persistent abdominal discomfort. 
 •  CT Abdomen (Image 3) showed peripancreatic abnormality. 
 •  Endoscopic Ultrasound with biopsy of the peripancreatic 
lymph node showed well differentiated neuroendocrine 
carcinoma. 
 •  Octreoscan showed findings similar to the CT Abdomen. 
 •  Further evaluation with 68Ga-DOTATATE PET/CT scan 
(Image 4a and 4b) showed hyperactive octreotide-avid 
peripancreatic and portocaval metastatic lymphadenopathy. 
 •  Patient underwent Whipple’s procedure and is currently 
being followed with serial 68Ga-DOTATATE PET/CT scans 
with no disease recurrence despite the primary still not being 
determined.
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